Concord Biotech Q4 Results
- BSE: 543960
- NSE: CONCORDBIO
- ISIN: INE338H01029
- Sector: Biotechnology & Drugs
BSE
1,240.00
-43.50 (-3.39%)
-43.50 (-3.39%)Volume9.34 K
Updated: Wed 11 Feb, 2026 | 15:29:58
NSE
1,244.80-37.50 (-2.92%)
-37.50 (-2.92%)Volume1.02 L
Updated: Wed 11 Feb, 2026 | 15:51:42
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q4 Results Highlights
Quarter ended Mar 25
Note: Comparison is on QoQ basis
Quarterly - Concord Biotech Q4 Results
*All figures in crores except per share values
| Fiscal Period | Mar 25 | Dec 24 | QoQ Comp | Mar 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 254.08 | 159.53 | 59.26% | 198.40 | 28.06% |
| Depreciation/ Amortization | 14.62 | 13.26 | 10.20% | 13.72 | 6.55% |
| Operating Income | 175.81 | 84.69 | 107.59% | 120.57 | 45.81% |
| Net Income | 140.39 | 75.92 | 84.91% | 95.02 | 47.75% |
| Other Operating Expenses Total | -40.23 | 59.23 | 0.00% | 61.88 | 0.00% |
| Net Income Before Taxes | 183.54 | 101.15 | 81.45% | 128.72 | 42.59% |
| Total Revenue | 429.88 | 244.22 | 76.02% | 318.97 | 34.77% |
| Selling/ General/ Admin Expenses Total | 38.97 | 34.64 | 12.49% | 33.96 | 14.76% |
| Diluted Normalized EPS | 13.41 | 7.26 | 84.72% | 9.08 | 47.69% |